Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

NCT03108131 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
49
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

M.D. Anderson Cancer Center

Collaborators